Key facts
- SynDevRx’s last known valuation is $120.0M.
- It has raised $93.8M across 6 recorded rounds; the latest was Early Stage VC ($29.4M) in Sep 2024.
- Notable investors include United States Department of War.
- SynDevRx has filed 23 Form Ds with the SEC since 2009, most recently Nov 2025 ($6.5M sold to 7 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 6 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for SynDevRx
Funding rounds
6 roundsAbout SynDevRx
Developer of therapeutic approaches designed to target the metabolic drivers and vascular factors that influence cancer progression. The company offers treatments grounded in metabo oncology and supported by ongoing clinical research in breast and prostate cancer, enabling clinicians and cancer patients to gain deeper disease insight and more targeted medical intervention.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2007
- Employees
- 5
- Website
- syndevrx.com/
- Ownership
- Privately Held (backing)
SynDevRx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SynDevRx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SynDevRx in its N-PORT filings yet. We sweep new filings monthly.